Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2001 March;45(1) > The Quarterly Journal of Nuclear Medicine 2001 March;45(1):91-9

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  NUCLEAR MEDICINE APPLICATIONS FOR BONE METASTASES


The Quarterly Journal of Nuclear Medicine 2001 March;45(1):91-9

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis

Serafini A. N.

From the Division of Nuclear Medicine University of Miami School of Medicine, Miami, Florida, USA


FULL TEXT  


Various radio­iso­topes con­ju­gat­ed to pyro­sphos­phate ana­logues ­have ­been devel­oped for system­ic meta­bol­ic radio­ther­a­py. Samarium-153-­EDTMP is a 1:1 com­plex of radio­ac­tive Samarium-153 and a Tetraphosphonate [eth­y­len­e­di­a­mine-tet­ra­meth­yl­ene phos­phon­ic ­acid (­EDTMP)]. Samarium Sm-153-­EDTMP has a ­high affin­ity for skel­e­tal tis­sue and con­cen­trates by chem­iab­sorp­tion in are­as of ­enhanced meta­bol­ic activ­ity, ­where it asso­ciates ­with the hydrox­yap­pe­tite crys­tal. Samarium-153 Lexidronam [Quadramet (R)] has ­been ­approved for rou­tine use by the FDA. This ­agent ­offers sev­er­al advan­tag­es ­over oth­er ­agents ­used for pal­li­at­ing ­bone ­pain. Due to its ­half-­life of 46 ­hours and its ­beta emis­sions, a ­high ­dose ­rate can be deliv­ered to ­regions adja­cent to ­enhanced oste­o­blas­tic activ­ity ­over a ­short peri­od of ­time ­with lit­tle resid­u­al ­long ­term activ­ity ­being ­left in the ­bone mar­row. This ­paper sum­mariz­es ­both ani­mal stud­ies and clin­i­cal stud­ies per­formed ­with ­this ­agent. Special empha­sis ­will be giv­en to the piv­ot­al Phase-III clin­i­cal stud­ies and sub­se­quent stud­ies per­formed ­since its approv­al by the FDA. Special con­sid­er­a­tions regard­ing appro­pri­ate selec­tion of ­patients, prep­ar­a­tion, fol­low-up of ­patients and adjust­ments to the usu­al rec­om­mend­ed ­dose [1 mCi/kg (35 Mbq/kg)] ­will be dis­cussed. Current and ­future treat­ment ­options uti­liz­ing Sm-153-­EDTMP ­with oth­er phar­ma­ceu­ti­cals ­appear prom­is­ing and ­will sub­stan­tial­ly ­extend its use ­into new are­as. In addi­tion, ­because it ­also ­emits a 103 keV gam­ma ray ­which ­makes it suit­able for imag­ing and assess­ment of bio­dis­trib­u­tion, dos­i­met­ric appli­ca­tions are pos­sible in the ­future.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail